Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
35 results
D3.140 - Transcriptomic profiling reveals distinct gene signatures and immune pathways in inhaled corticosteroid (ICS)-sensitive and resistant House Dust Mite (HDM)-induced asthma mouse models
D3.141 - Serum levels of IL-10 and IFN-GAMMA in adolescents diagnosed with asthma in clinical remission without treatment
D3.142 - Adherence to Inhaled Corticosteroid Therapy in Patients with Severe Asthma at a Danish Tertiary Care Centre
D3.143 - Immunomodulatory role of vitamin D in severe asthma: a potential biomarker of treatment response
D3.144 - Did allergic status change the quality of life in controlled severe asthma patients with triple therapy?
D3.145 - Comparative particle size and distribution from fixed dose triple dry powder inhalers
D3.146 - Attitudes and Knowledge Levels Regarding Physical Activity in Children with Asthma and Their Parents: A Comparison with Healthy Controls
D3.147 - A Survey of Approaches to Inhaled Therapy Management in Patients with Severe Asthma Treated with Biologics: Practices Among REIMAGINE Study Sites
D3.148 - ANCA-Negative Systemic Vasculitis Developing Despite Anti-IL-5R Therapy and High Dose of Glucocorticosteroids: A Diagnostic and Therapeutic Challenge
D3.149 - Nationwide Trends in Asthma-Related Mortality in Türkiye: Impact of the Sex-Specific Differences (2018–2024)
D3.150 - Clinical characterization of patients affected by asthma and psoriasis or psoriasic arthritis: an observational retrospective study
D3.151 - Anti-IL5 biologics in eosinophilic granulomatosis with polyangiitis patients followed in a severe asthma multidisciplinary unit: functional and clinical outcomes
D3.152 - The quality of life in severe asthma patients treated with biologics is better than those with triple inhaler therapy
D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download